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IMP-3 expression in melanocytic
lesions
Background: Insulin-like growth factor-II mRNA-binding protein 3
(IMP-3), a member of the insulin-like growth factor mRNA-binding
protein family, is expressed in several human malignancies, including
melanomas. However, the expression of IMP-3 has not been explored
in melanoma in situ, various histologic subtypes of invasive melanomas
and atypical Spitz tumors.
Methods: IMP-3 immunostain was performed in 157 melanocytic
lesions.
Results: Nearly all benign (8/8), dysplastic (8/8) and Spitz nevi (8/9)
were negative for IMP-3. Focal IMP-3 positivity was observed in 5/12
melanoma in situ and 4/15 superficial melanomas (Breslow depth
≤1 mm). Half (10/20) of deep melanomas (Breslow depth >1 mm) and
25/52 metastatic melanomas demonstrated strong IMP-3 staining.
IMP-3 expression differs significantly between non-desmoplastic
melanomas (superficial and deep) and benign or dysplastic or Spitz nevi
(p = 0.0427, respectively). Four of 23 desmoplastic melanomas
expressed IMP-3, which was significantly different from deep
melanomas (p = 0.0109). IMP-3 stained 7 of 10 atypical Spitz tumors.
The difference between atypical Spitz tumors and Spitz nevi was
statistically significant (p = 0.0256).
Conclusion: A malignant circumstance, such as non-desmoplastic
melanoma or atypical Spitz tumor, can be inferred when IMP-3 is
expressed, suggesting potential diagnostic value of IMP-3 in
melanocytic lesions.
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Malignant melanoma is a life-threatening cutaneous
cancer. Its incidence and mortality has risen
worldwide.1 The diagnosis of melanocytic lesions is
mainly based on a number of well-defined histology
criteria, but remains one of the most challenging
areas in dermatopathology. Interobserver differences
are not infrequently encountered for difficult lesions.2
Despite advances in melanoma research, no reliable
diagnostic and/or prognostic markers have yet been
identified.
Insulin-like growth factor-II (IGF-II) mRNA-
binding protein 3 (IMP-3), also known as K
homology domain-containing protein overexpressed
in cancer (KOC) or L523S, is a member of the
insulin-like growth factor mRNA-binding protein
family.3 Located on chromosome 7p11.5, IMP-3
gene encodes a 580-amino acid protein that binds
to IGF-II transcripts and is involved in the post-
transcriptional regulation of cell proliferation during
embryogenesis. Its expression is limited in normal
mature tissue.3,4 Since IMP-3 was first cloned
from pancreatic carcinomas, it has been detected
in cervical adenocarcinoma, renal cell carcinoma,
urothelial carcinoma and other malignancies.5– 7
Additionally, IMP-3 was shown to be an independent
prognostic marker in renal cell carcinoma and its
expression in early stage lesions could help identify
patients with high potential to develop metastasis.5
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Data from in vitro IMP-3 knockdown study and
from IMP-3 administration in patients with lung
cancer indicate that IMP-3 may be a promising
therapeutic target for human malignancies.8,9 A
recent study demonstrated that IMP-3 was expressed
in malignant melanomas but not in nevi.10 However,
the expression of IMP-3 in melanoma in situ (MIS),
desmoplastic melanoma and atypical Spitz tumor
(AST) has not been examined in the literature.
Interestingly, IMP-1, another member of IMP family
protein, was recently found to be elevated in primary
human melanomas and melanoma cell lines.11
In this study, we investigated the expression of
IMP-3 in a spectrum of cutaneous melanocytic
lesions, including benign/dysplastic/Spitz nevus,
MIS, primary melanoma (non-desmoplastic and
desmoplastic melanoma), AST and metastatic
melanoma. We further assessed the diagnostic and
prognostic utility of IMP-3 in melanocytic lesions.
Materials and methods
Case selection
This study was approved by the Institutional Review
Board at the University of Michigan Health System.
A broad range of melanocytic lesions was identified
through a search of the pathology database from
the Department of Pathology at the University
of Michigan. As shown in Table 1, the study
group included 8 benign nevi, 8 dysplastic nevi,
9 Spitz nevi, 12 MIS, 58 primary melanomas (35
non-desmoplastic and 23 desmoplastic melanomas),
52 metastatic melanomas and 10 ASTs. The
histologic subtypes of non-desmoplastic melanomas
were superficial spreading (21), lentigo maligna
(5), nodular (4), nevoid (1), Spitzoid (1) and
acral lentiginous types (3). Based on the Breslow
depth, non-desmoplastic melanomas were further
separated into superficial (depth ≤1.0 mm) and deep
melanomas (depth >1.0 mm). Sentinel lymph node
(SLN) biopsies were performed on 19 of 20 patients
with deep melanomas. Five showed nodal metastases,
while one patient with negative SLNs had bone
metastasis (Table 4). All desmoplastic melanomas
had a Breslow depth greater than 1.0 mm. SLN
biopsies were performed on 21 cases, 3 of which were
positive. All ASTs had a depth greater than 1 mm.
Among eight cases with SLN biopsies available, six
showed microscopic tumor deposits (minute foci),
one had <5% surface area involved and one was
negative.
The hematoxylin and eosin-stained slides were
reviewed to confirm the diagnoses. Important
prognostic information, such as Breslow depth,
mitotic rate and SLN status, was collected for
primary invasive melanomas (see Table 4). The
pathologic and clinical stages were determined
using the American Joint Committee on Cancer
(AJCC) staging system.12 Unstained whole tissue
sections were available for all nevi, all MIS,
most non-desmoplastic melanomas, five desmoplastic
melanomas and six metastatic melanomas. Three
non-desmoplastic melanomas and the rest of
desmoplastic and metastatic melanomas were
derived from tissue microarray sections.
Immunohistochemistry
Formalin-fixed paraffin-embedded 4-μm tissue
sections were deparaffinized and pretreated with
3% H2O2 and Tris buffer saline (TBS). After
antigen retrieval, the sections were incubated with
a monoclonal mouse anti- IMP-3/L523S antibody
(1:100 dilution; clone 69.1; Dako, Carpinteria, CA,
USA) at room temperature for 40–60 min and
then with EnVision+ System horseradish peroxidase
(HRP) labeled polymer conjugated to goat anti-
mouse (Dako) for 30 min. Staining was achieved
with 3-amino-9-ethylcarbazole (AEC)+Substrate-
Chromogen (Dako) for 10 min. Tissue from large
cell neuroendocrine carcinoma of the lung was used
as positive control.
Table 1. Clinical characteristics of the patients
N Average age (range) M : F (%)
Benign nevus 8 34 (14–46) 25/75
Dysplastic nevus 8 39 (20–71) 50/50
Spitz nevus 9 20 (5–61) 56/44
Melanoma in situ 12 67 (22–85) 58/42
Non-desmoplastic melanoma 35 57 (29–94) 54/46
Desmoplastic melanoma 23 62 (23–92) 70/30
Metastatic melanoma 52 54 (20–83) 67/33
Atypical Spitz tumor 10 15 (6–41) 30/70
N, total numbers of cases; M, male; F, female.
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Table 2. The percentage of tumor cells stained with IMP-3 in melanocytic lesions
N Negative <10% 10–50% >50% ≥10%
Nevus 25 24 (96.0%) 1 (4.0%) 0 (0%) 0 (0%) 0 (0%)∗
benign nevus 8 8 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
dysplastic nevus 8 8 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Spitz nevus 9 8 (88.9%) 1 (11.1%) 0 (0%) 0 (0%) 0 (0%)
Melanoma in situ 12 7 (58.3%) 5 (41.7%) 0 (0%) 0 (0%) 0 (0%)
Non-desmoplastic melanoma 35 21 (60.0%) 1 (2.9%) 7 (20.0%) 6 (17.1%) 13 (37.1%)
melanoma ≤1 mm 15 11 (73.3%) 1 (6.7%) 3 (20.0%) 0 (0%) 3 (20.0%)
melanoma >1 mm 20 10 (50.0%) 0 (0%) 4 (20.0%) 6 (30.0%) 10 (50.0%)
Desmoplastic melanoma 23 19 (82.6%) 1 (4.3%) 2 (8.7%) 1 (4.3%) 3 (13.0%)†
Metastatic melanoma 52 25 (48.1%) 2 (3.8%) 2 (3.8%) 23 (44.2%) 25 (48.1%)
Atypical Spitz tumor 10 3 (30.0%) 2 (20.0%) 2 (20.0%) 3 (30.0%) 5 (50%)‡
∗p = 0.0251 when compared with non-desmoplastic melanoma.
†p = 0.0109 when compared with melanoma >1 mm.
‡p = 0.0256 when compared with Spitz nevus.
Cytoplasmic staining was considered positive for
IMP-3. The percentage of positive cells was recorded
as negative (0), <10% (1+), 10–50% (2+) or >50%
(3+). The staining intensity was graded as weak (1+),
moderate (2+) or strong (3+). Two pathologists (LY
and LM) independently recorded the staining results.
The two had complete concordance in scoring a case
positive or negative and reached general consensus
as regard to the percentage and intensity of positive
staining.
Statistical analysis
Statistical analysis was carried out using SAS
8.2 software (SAS Institute Inc., Cary, NC). The
Fisher’s exact test was used to assess the differences
in IMP-3 expression among various melanocytic
lesions. A p value <0.05 was considered statistically
significant.
Results
In normal skin, IMP-3 did not label any epidermal
or dermal structures (data not shown).
The clinical characteristics of the 157 melanocytic
lesions are listed in Table 1. Table 2 and 3
summarize IMP-3 immunostain results. One Spitz
nevus displayed IMP-3 positivity in less than 10%
of the lesional cells. All other benign, dysplastic and
Spitz nevi were negative for IMP-3 (Fig. 1A–C).
Five of 12 (41.7%) cases of MIS demonstrated
moderate IMP-3 staining in less than 10% of the
tumor cells. The positive cells were arranged as iso-
lated single cells or rare small aggregates (Fig. 2A).
Similarly, focal IMP-3 positivity was detected in
a subset (4/15) of superficial melanomas (depth
≤1 mm) with most cases (3/4) demonstrating strong
intensity in at least 10% of the tumor cells (Fig. 2B).
Compared to MIS, the in situ component of super-
ficial melanomas above the dermal invasion was
marked as continuous linear arrays rather than dis-
crete single cells (Fig. 2B). Half (10/20) of deep
melanomas (depth >1.0 mm) expressed IMP-3 in
at least 10% of the tumor cells with most (8/10)
having moderate to strong intensity (Fig. 2C). The
expression of IMP-3 in non-desmoplastic melanomas
(superficial and deep) was significantly different from
that in benign nevi, dysplastic nevi or Spitz nevi
(p = 0.0427 individually; p = 0.0251 when all nevi
combined). The difference between superficial and
deep melanomas was not significant (p = 0.0916).
As shown in Table 4, the expression of IMP-3 in
non-desmoplastic melanomas appeared to be inde-
pendent of age, sex, histologic subtype and other
important prognostic factors. Interestingly, only a
small subset of desmoplastic melanomas (4/23;
17.4%) expressed IMP-3 with moderate to strong
intensity (Fig. 2D). The staining was significantly dif-
ferent between desmoplastic and non-desmoplastic
deep melanomas (p = 0.0109).
Fig. 1. (A) A benign nevus, (B) a dysplastic nevus
and (C) a Spitz nevus stained negative for
IMP-3 (×400).
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Fig. 2. (A) A case of MIS demonstrated weak IMP-3 positivity with single cell pattern. (B) Focal and strong IMP-3 staining in superficial
melanoma (Breslow depth ≤1 mm). The in situ component of superficial melanomas was stained mostly as confluent tumor nests. (C) Deep
melanoma (Breslow depth >1.0 mm) showing diffuse and strong IMP-3 staining. (D) A case of desmoplastic melanoma with moderate IMP-3
positivity. (E) Strong IMP-3 staining in metastatic melanoma. (F) Moderate IMP-3 labeling in a case of AST (×400).
Table 3. IMP-3 staining intensity in melanocytic lesions
N Negative Weak Moderate Strong
Nevus 25 24 (96.0%) 0 (0%) 1 (4.0%) 0 (0%)
benign nevus 8 8 (100%) 0 (0%) 0 (0%) 0 (0%)
dysplastic nevus 8 8 (100%) 0 (0%) 0 (0%) 0 (0%)
Spitz nevus 9 8 (88.9%) 0 (0%) 1 (11.1%) 0 (0%)
Melanoma in situ 12 7 (58.3%) 0 (0%) 5 (41.7%) 0 (0%)
Non-desmoplastic melanoma 35 21 (60.0%) 3 (8.6%) 2 (5.7%) 9 (25.7%)
melanoma ≤1 mm 15 11 (73.3%) 1 (6.7%) 0 (0%) 3 (20.0%)
melanoma >1 mm 20 10 (50.0%) 2 (10.0%) 2 (10.0%) 6 (30.0%)
Desmoplastic melanoma 23 19 (82.6%) 0 (0%) 3 (13.0%) 1 (4.4%)
Metastatic melanoma 52 25 (48.1%) 1 (1.9%) 8 (15.4%) 18 (34.6%)
Atypical Spitz tumor 10 3 (30.0%) 3 (30.0%) 3 (30.0%) 1 (10.0%)
Similar to non-desmoplastic deep melanomas,
27/52 (51.9%) metastatic melanomas were positive
for IMP-3 (Fig. 2E). Nearly all (26/27) showed
moderate to strong staining and most (23/27)
stained diffusely. No significant difference was
attained between deep melanomas and metastatic
melanomas.
Unlike Spitz nevus, most ASTs (7/10; 70%)
expressed IMP-3, with five showing staining in at least
10% of tumor cells and six having weak to moderate
intensity (Fig. 2F). There was a statistical difference
between AST and Spitz nevus (p = 0.0256). But
IMP-3 expression between AST and deep melanoma
was not significantly different (p = 0.686).
Discussion
Our study investigated for the first time the expression
of IMP-3 in MIS, desmoplastic melanoma and AST.
The expression of IMP-3 was significantly differ-
ent between primary non-desmoplastic melanomas
and benign/dysplastic/Spitz nevi (p = 0.0427 indi-
vidually; p = 0.0251 when all nevi combined). Our
findings confirm Pryor’s observation10 and sug-
gest that a diagnosis of melanomas as opposed
to melanocytic nevi may be inferred when IMP-3
is strongly expressed. Interestingly, Pryor et al.10
observed that 2 of 10 Spitz nevi showed diffuse
IMP-3 staining, while only 1 Spitz nevus in our
study showed positivity in <10% of tumor cells. It is
unclear what may have attributed to this difference.
Future studies with more Spitz nevi included would
be helpful to address the issue.
We observed discrete and isolated single IMP-3-
positive cells in MIS. However, because the staining
was limited to <10% of tumor cells, IMP-3 is less
likely to be of any use in separating MIS from
dysplastic nevus. Conventional histology remains the
most important tool in diagnosing MIS.
Recently, IMP-3 was shown to be an independent
prognostic marker in renal cell carcinoma and
urothelial carcinoma to identify patients who had
high metastatic potential.5,7,13 Previously, Pryor
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Table 4. Clinical characteristics and IMP-3 staining in primary non-desmoplastic melanomas










1 74 M SSM T1aNxMx 0.26 no no insuf 2 ND 2+ 3+
2 55 M SSM T1aNxMx 0.27 no yes insuf 2 ND 0 0
3 81 F SSM T1aNxMx 0.34 no yes 0 2 ND 2+ 3+
4 52 M SSM T1aNxMx 0.35 no no 0 1 ND 0 0
5 73 M LMM T1aNxMx 0.41 no no 4 1 ND 2+ 3+
6 70 M LMM T1aNxMx 0.43 no no 0 1 ND 0 0
7 41 F SSM T1aNxMx 0.44 no no insuf 2 ND 0 0
8 45 F SSM T1aNxMx 0.48 no no 0 2 ND 0 0
9 63 F SSM T1aNxMx 0.55 no yes insuf 1 ND 0 0
10 59 M SSM T1bNxMx 0.55 no yes insuf 2 ND 0 0
11 61 F SSM T1aNxMx 0.56 no yes 0 2 ND 0 0
12 40 M SSM T1aNxMx 0.60 no no insuf 1 ND 0 0
13 48 M SSM T1aNxMx 0.63 no yes 0 2 ND 0 0
14 57 M SSM T1aNxMx 0.64 no yes insuf 1 ND 0 0
15 53 M LMM T1bNxMx 0.82 no no 0 2 ND 1+ 1+
16 74 F SSM T2aN0Mx 1.01 no no 1 2 neg 2+ 2+
17 43 F ALM T2bN2bM1a 1.15 yes no 0 1 pos 0 0
18 73 M SSM T2aN0Mx 1.16 no no 0 1 neg 0 0
19 66 M SSM T2aN0Mx 1.16 no no 0 1 neg 3+ 3+
20 64 M SSM T2aN0Mx 1.46 no no 0 1 neg 2+ 2+
21 85 M LMM T2aN0Mx 1.57 no no 3 2 neg 3+ 3+
22 51 F SSM T3aN0M1c 1.7 no no 2.5 2 neg∗ 0 0
23 76 M NO T3aN0Mx 2.4 no no 6 1 neg 0 0
24 44 M SSM T3aN0Mx 2.4 no yes 0 1 neg 0 0
25 94 F LMM T3aNxMx 2.5 no no 3 1 ND 3+ 3+
26 39 F SSM T3aN2bMx 2.5 no no 2 1 pos 3+ 3+
27 72 M NO T3aN2bMx 2.9 no yes 11 2 pos 3+ 3+
28 40 F NE T3aN3Mx 3.05 no no 3.5 1 pos 0 0
29 51 F SSM T3aN0Mx 3.6 no no 2 1 neg 2+ 1+
30 29 M NO T3aN0Mx 3.65 no no 1.5 1 neg 0 0
31 50 F SSM T3aN0Mx 3.75 no no 1.5 1 neg 3+ 3+
32 51 F ALM T4bN0Mx 4.1 yes no 3.5 1 neg 0 0
33 34 F NO T4aN0Mx 4.5 no no 1 2 neg 0 0
34 38 F SPM T4aN1bMx 5.25 no no 1 2 pos 2+ 1+
35 46 M ALM T4bN0Mx 7.1 yes no 3 1 neg 0 0
∗Bone metastasis identified.
SSM, superficial spreading melanoma; LMM, lentigo maligna melanoma; ALM, acral lentiginous melanoma; NE, nevoid melanoma; NO, nodular
melanoma; SPM, Spitzoid melanoma; TNM, Pathologic T (tumor) stage, N (nodal), M (metastasis); insuf, insufficient tumor volume for count;
TIL, tumor infiltrating lymphocytes (1, non-brisk; 2, brisk); ND, not done.
et al.10 found that IMP-3 was expressed at
lower levels in superficial melanomas than deep
melanomas, but the difference between the two
was not statistically significant. In concordance with
their findings, we also noted stronger and more
diffuse IMP-3 staining in deep melanomas than
in superficial melanomas. However, there was no
statistical difference between superficial and deep
melanomas (p = 0.0916). In addition, when deep
melanomas were compared at incremental Breslow
depth (Table 4), no significant correlation was
detected between IMP-3 levels and tumor depths,
other melanoma prognostic factors or clinical stages.
Our findings suggest that IMP-3 is probably of no
value in predicting melanomas with greater risk to
metastasize and/or shorter survival intervals. IMP-3
does not seem to play a role in melanoma tumor
progression. Future studies with additional cases are
necessary to substantiate our observation.
Desmoplastic melanoma is an uncommon fibros-
ing variant of melanoma, which usually reacts
with S100 protein, but is often negative for other
melanocytic markers.14 It differs from conventional
melanoma in its higher local recurrence rate and
relatively infrequent involvement of regional lymph
node. However, the survival rates for desmoplastic
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melanoma patients are similar to those for patients
with other types of melanomas at comparable
thickness.15– 17 It was recently shown that γ–H2AX,
a marker of activated DNA damage, was over-
expressed in most primary cutaneous melanomas
except desmoplastic melanomas.18 Our observa-
tion of lower IMP-3 expression in desmoplastic
melanomas compared to other deep melanomas
(p = 0.0109) is interesting. We suspect that the
unique desmoplastic stromal response in desmoplas-
tic melanoma may be related to the limited expression
of many common molecules that are upregulated in
other melanomas.
AST is a borderline melanocytic lesion with
uncertain biologic potential.19 It shows overlapping
histologic features seen in both Spitz nevus and
Spitzoid melanoma. AST generally does not
meet the diagnostic threshold for melanoma, but
demonstrates concerning features, such as large
size, asymmetry, aberrant dermal growth pattern,
incomplete maturation, cytologic atypia, increased
dermal mitotic rates and deep dermal mitoses.19– 21
Unlike conventional melanoma, patients with AST
carry a favorable prognosis, despite a high incidence
of microscopic SLN deposits.22 Occasionally,
differentiating AST from melanoma or Spitz nevus
can be problematic. Among a number of tests (i.e.
p53, Ki-67 index and fatty acid synthase) studied
in the past, comparative genomic hybridization
(CGH) appears to hold promise in determining
the malignant potential of some controversial
melanocytic lesions, including AST.23– 26 In this
study, we found that the expression of IMP-3 was
significantly different between Spitz nevus and AST
(p = 0.0256), indicating IMP-3 may be helpful in
differentiating AST from Spitz nevus. Although deep
melanoma showed stronger IMP-3 staining intensity
than AST, the lack of statistical difference argues
against its diagnostic value in differentiating the two.
In summary, this is the first study to demonstrate
the expression of IMP-3 in MIS, desmoplastic
melanoma and AST. Our findings confirm the
potential diagnostic utility of IMP-3 in differentiating
melanocytic nevus from melanoma and in separating
Spitz nevus from AST, when a positive IMP-3
expression is observed. As IMP-3 was expressed
at high levels in deep melanoma and metastatic
melanoma, it may serve as an intriguing therapeutic
target for malignant melanomas.
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